CSIMarket
 


Exact Sciences Corporation  (EXAS)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

EXAS's Capital Expenditures Growth by Quarter and Year

Exact Sciences's Capital Expenditures results by quarter and year




EXAS Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 34.92 72.88 1.32 16.57
III Quarter September 25.19 44.64 38.87 14.33
II Quarter June 34.72 63.33 57.66 20.77
I Quarter March 29.36 33.62 37.92 12.69
FY   124.19 214.47 135.77 64.36



EXAS Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Exact Sciences Corporation reported drop in Capital Expenditures in the fourth quarter 2023 by -52.08% to $ 34.92 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Exact Sciences Corporation's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures jump of 95.52%.

According to the results reported in the fourth quarter 2023, Exact Sciences Corporation achieved the best Capital Expenditures growth in Medical Laboratories industry. While Exact Sciences Corporation' s Capital Expenditures meltdown of -52.08% ranks overall at the positon no. 97 in the fourth quarter 2023.




EXAS Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -52.08 % 5421.21 % -92.03 % -58.88 %
III Quarter September -43.57 % 14.84 % 171.25 % -72.27 %
II Quarter June -45.18 % 9.83 % 177.61 % -69.91 %
I Quarter March -12.67 % -11.34 % 198.82 % 17.5 %
FY   -42.09 % 57.97 % 110.95 % -62.54 %

Financial Statements
Exact Sciences's fourth quarter 2023 Capital Expenditures $ 34.92 millions EXAS's Income Statement
Exact Sciences's fourth quarter 2022 Capital Expenditures $ 72.88 millions Quarterly EXAS's Income Statement
New: More EXAS's historic Capital Expenditures Growth >>


EXAS Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 38.63 % 63.26 % -96.6 % 15.63 %
III Quarter September -27.45 % -29.51 % -32.59 % -31.01 %
II Quarter June 18.26 % 88.37 % 52.06 % 63.67 %
I Quarter March -59.71 % 2446.97 % 128.85 % -68.51 %
FY (Year on Year)   -42.09 % 57.97 % 110.95 % -62.54 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #11
Overall #97

Capital Expenditures Y/Y Growth Statistics
High Average Low
848.07 % 95.52 % -62.54 %
(March 31, 2014)   (Dec 31 2020)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #11
Overall #97
Capital Expenditures Y/Y Growth Statistics
High Average Low
848.07 % 95.52 % -62.54 %
(March 31, 2014)   (Dec 31 2020)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Exact Sciences's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2449.13 % 86.56 % -100 %
(Mar 31 2022)  


EXAS's IV. Quarter Q/Q Capital Expenditures Comment
Exact Sciences Corporation achieved in the IV. Quarter 2023 below company average Capital Expenditures jump of 38.63% quarter on quarter, to $ 34.92 millions.

Within Medical Laboratories industry Exact Sciences Corporation achieved highest sequential Capital Expenditures growth. While Exact Sciences's Capital Expenditures growth quarter on quarter, overall rank is 211.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #27
Overall #211
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #27
Overall #211
Capital Expenditures Q/Q Growth Statistics
High Average Low
2449.13 % 86.56 % -100 %
(Mar 31 2022)  


EXAS's IV. Quarter Q/Q Capital Expenditures Comment
Exact Sciences Corporation achieved in the IV. Quarter 2023 below company average Capital Expenditures jump of 38.63% quarter on quarter, to $ 34.92 millions.

Within Medical Laboratories industry Exact Sciences Corporation achieved highest sequential Capital Expenditures growth. While Exact Sciences's Capital Expenditures growth quarter on quarter, overall rank is 211.


Exact Sciences's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 124.19 $ 162.14 $ 181.59 $ 210.20 $ 214.46
Y / Y Capital Expenditures Growth (TTM) -42.09 % 13.46 % 32.42 % 59.88 % 57.96 %
Year on Year Capital Expenditures Growth Overall Ranking # 84 # 1361 # 670 # 402 # 249
Seqeuential Capital Expenditures Change (TTM) -23.41 % -10.71 % -13.61 % -1.99 % 50.07 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 97 # 1289 # 726 # 999 # 1405




Cumulative Capital Expenditures growth Comment
For the 12 months ended Dec 31 2023 Exact Sciences reported a drop in Capital Expenditures by -42.09% year on year, to $124 millions, compare to the 13.46% growth at Sep 30 2023.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 84, from total ranking in previous quarter at 1361.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
848.07 %
95.52 %
-62.54 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 0
Healthcare Sector # 11
Overall # 84

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
848.07 %
95.52 %
-62.54 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 11
S&P 500 # 97
Cumulative Capital Expenditures growth Comment
For the 12 months ended Dec 31 2023 Exact Sciences reported a drop in Capital Expenditures by -42.09% year on year, to $124 millions, compare to the 13.46% growth at Sep 30 2023.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 84, from total ranking in previous quarter at 1361.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
848.07 %
95.52 %
-62.54 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 0
Healthcare Sector # 11
Overall # 84

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
848.07 %
95.52 %
-62.54 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 11
S&P 500 # 97




Other Capital Expenditures Growth
Medical Laboratories Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
EXAS's Capital Expenditures Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for EXAS's Competitors
Capital Expenditures Growth for Exact Sciences's Suppliers
Capital Expenditures Growth for EXAS's Customers

You may also want to know
EXAS's Annual Growth Rates EXAS's Profitability Ratios EXAS's Asset Turnover Ratio EXAS's Dividend Growth
EXAS's Roe EXAS's Valuation Ratios EXAS's Financial Strength Ratios EXAS's Dividend Payout Ratio
EXAS's Roa EXAS's Inventory Turnover Ratio EXAS's Growth Rates EXAS's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com